New Wave Wealth Advisors LLC Invests $464,000 in Teva Pharmaceutical Industries Ltd. $TEVA

New Wave Wealth Advisors LLC bought a new stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) in the 3rd quarter, according to its most recent filing with the SEC. The fund bought 22,960 shares of the company’s stock, valued at approximately $464,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. AQR Capital Management LLC increased its stake in shares of Teva Pharmaceutical Industries by 24.6% in the 1st quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock valued at $368,000 after purchasing an additional 4,732 shares in the last quarter. Focus Partners Wealth increased its stake in Teva Pharmaceutical Industries by 4.5% during the 1st quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock worth $616,000 after buying an additional 1,739 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Teva Pharmaceutical Industries by 65.9% during the second quarter. GAMMA Investing LLC now owns 7,282 shares of the company’s stock valued at $122,000 after acquiring an additional 2,892 shares during the last quarter. Fifth Third Bancorp boosted its stake in shares of Teva Pharmaceutical Industries by 49.2% in the second quarter. Fifth Third Bancorp now owns 32,805 shares of the company’s stock worth $550,000 after acquiring an additional 10,820 shares during the last quarter. Finally, Hartford Investment Management Co. increased its position in shares of Teva Pharmaceutical Industries by 30.9% during the second quarter. Hartford Investment Management Co. now owns 13,796 shares of the company’s stock worth $231,000 after purchasing an additional 3,257 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, CAO Amir Weiss sold 12,300 shares of the business’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $30.20, for a total transaction of $371,460.00. Following the sale, the chief accounting officer owned 5,650 shares of the company’s stock, valued at $170,630. The trade was a 68.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Mark Sabag sold 216,892 shares of the firm’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $28.73, for a total value of $6,231,307.16. Following the completion of the transaction, the insider directly owned 52,828 shares of the company’s stock, valued at $1,517,748.44. The trade was a 80.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 622,060 shares of company stock worth $17,076,965 in the last quarter. 0.49% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Stock Up 0.8%

TEVA opened at $31.66 on Friday. The stock has a market capitalization of $36.31 billion, a P/E ratio of 52.77, a price-to-earnings-growth ratio of 1.80 and a beta of 0.66. The company has a debt-to-equity ratio of 2.31, a quick ratio of 0.82 and a current ratio of 1.11. Teva Pharmaceutical Industries Ltd. has a one year low of $12.47 and a one year high of $33.42. The business’s 50-day simple moving average is $29.51 and its 200-day simple moving average is $22.48.

Analyst Ratings Changes

TEVA has been the topic of several research reports. JPMorgan Chase & Co. raised their price target on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 16th. The Goldman Sachs Group lifted their price objective on Teva Pharmaceutical Industries from $31.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday. Barclays assumed coverage on Teva Pharmaceutical Industries in a report on Tuesday, December 9th. They set an “overweight” rating and a $35.00 price target on the stock. Finally, Wall Street Zen downgraded shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Sunday, January 18th. Three research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Teva Pharmaceutical Industries has an average rating of “Buy” and an average target price of $33.67.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.